Cell Cycle Proteins and Cancer Therapy

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Biomacromolecules: Proteins".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 3407

Special Issue Editor


E-Mail Website
Guest Editor
Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020—UMR1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, 59000 Lille, France
Interests: immunotherapy; cancer; checkpoint inhibitors; resistance to cancer; tumor dormancy; melanoma; leukemia; microscale thermophoresis; cytometry; drug screening; in vitro cell culture; in vivo models

Special Issue Information

Dear Colleagues,

During the cell cycle of eukaryotic cells, many proteins are involved in regulation and maintenance. These proteins include kinases and cyclins that regulate movement between the different phases of the cell cycle (interphase, mitosis and cytokinesis), leading to replication and cell division.

Many human cancers exhibit the aberrant activity of various cell cycle proteins (such as cyclin-dependent kinases (CDKs), checkpoint kinases, Aurora kinases and polo-like kinases (PLKs)) and result in the uncontrolled proliferation of tumour cells, tumour dormancy, or recurrence. After decades of research aimed at understanding the functions of cell cycle proteins and their relevance in cancer, cell cycle regulators are now considered interesting targets for cancer treatment.

This Special Issue will focus on recent discoveries regarding the cell cycle proteins and their role in cancer therapy. We invite colleagues to submit their latest research or reviews covering the diagnostic and therapeutic aspects of cell cycle proteins in the broad field of oncology.  Topics may include new insights into the mechanisms and pathways involved in cell cycle regulation/control under physiological and pathophysiological conditions, as well as new insights into the regulation of cell cycle mediators/transducers in cancer cells in both in vitro and in vivo models. In addition, papers describing novel inhibitors that target cell cycle transducers in basic and/or clinical settings are welcome.

Dr. Xavier Thuru
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancers
  • cyclin-dependent kinases (CDKs)
  • checkpoint kinases
  • cyclin-dependent kinase inhibitors
  • tumor dormancy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

21 pages, 1624 KiB  
Systematic Review
An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer—A Systematic Review of Randomized Phase II and III Clinical Trials
by Ioana-Miruna Stanciu, Andreea Ioana Parosanu and Cornelia Nitipir
Biomolecules 2023, 13(9), 1422; https://doi.org/10.3390/biom13091422 - 20 Sep 2023
Cited by 3 | Viewed by 3049
Abstract
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have transformed the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) breast cancer over the last decade. These inhibitors are currently established as first- and second-line systemic treatment choices for both [...] Read more.
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have transformed the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) breast cancer over the last decade. These inhibitors are currently established as first- and second-line systemic treatment choices for both endocrine-sensitive and -resistant breast cancer populations alongside endocrine therapy (ET) or monotherapy. Data on targeted therapy continue to mature, and the number of publications has been constantly rising. Although these drugs have been demonstrated to prolong overall survival (as well as progression-free survival (PFS) in breast cancer patients), changing the paradigm of all current knowledge, they also cause important adverse events (AEs). This review provides the latest summary and update on the safety profile of the three CDK4/6 inhibitors, as it appears from all major phase II and III randomized clinical trials regarding palbociclib, ribociclib, and abemaciclib, including the most relevant 15 clinical trials. Full article
(This article belongs to the Special Issue Cell Cycle Proteins and Cancer Therapy)
Show Figures

Figure 1

Back to TopTop